Session » Abstracts: Metabolic & Crystal Arthropathies

Date: Monday, November 18, 2024

Time: 1:00PM-2:30PM

Meeting: ACR Convergence 2024

1:00PM-2:30PM: Abstract Number: 2561

Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

1:00PM-2:30PM: Abstract Number: 2560

Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study

1:00PM-2:30PM: Abstract Number: 2558

Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand

1:00PM-2:30PM: Abstract Number: 2562

Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases

1:00PM-2:30PM: Abstract Number: 2559

Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis

1:00PM-2:30PM: Abstract Number: 2557

The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].